AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01497691 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Volumetric CO2 (NM3)
Description: The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
Study NCT01497691 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: USCOM
Description: The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
Study NCT01497691 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: USCOM
Description: The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
Study NCT01497691 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: USCOM
Description: The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
Study NCT00371137 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xyrem®
Description: two doses
Study NCT00371137 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral Solution
Study NCT05237154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with intermittent fasting.
Description: Intervention with fasting protocol of alternate days 2 days a week and the other days with ad libitum consumption. Restricted food in 25% of the total daily needs on the days of the intermittent fasting protocol, with 18 hours of fasting and 6 hours of restricted feeding (18:6).
Study NCT05237154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention with high-intensity interval training.
Description: Intervention with high-intensity interval training, 3x per week, with intensity maintained between 70-85% of maximum heart rate.
Study NCT02314611 — intervention group
Intervention type: DEVICE
Intervention: PROFEMUR® Gladiator HA Coated Modular Femoral Stem
Description: Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
Study NCT01108302 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxytocin in Uniject
Description: 10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
Study NCT00848705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YourWay Internet Intervention
Description: The intervention is an 11 week program that teaches problem solving of barriers to self-management.
Study NCT00848705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YourWay Internet Intervention
Description: The intervention is an 11 week program that teaches problem solving of barriers to self-management.
Study NCT02432014 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PMTO-PTC Group clinic-based
Study NCT02432014 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PMTO Individual home-based
Study NCT02432014 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: PMTO Individual clinic-based
Study NCT02432014 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Services as Usual
Study NCT03055260 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction cuff
Description: The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
Study NCT03055260 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Blood Flow restriction Cuff-Placebo
Description: The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
Study NCT00441883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-03187207 and Latanoprost Vehicle
Study NCT00441883 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% and PF-03187207 Vehicle
Study NCT00822835 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ILV-095
Study NCT00822835 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01053884 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Anidulafungin
Description: standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.~Prophylaxis will be given until the recovery from neutropenia (ANC > 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture.
Study NCT02732704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JenaValve Pericardial TAVR System
Description: TAVR with JenaValve Pericardial Valve and Delivery System
Study NCT05708287 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFNC
Description: The patients with mild hypoxemia, defined as the need for conventional oxygen therapy (COT) using nasal cannula at 4-5 liters per minute (LPM) to maintain O2 Saturation >90%, were commenced on HFNC therapy
Study NCT01294657 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health Education
Description: Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
Study NCT01294657 — intervention group
Intervention type: BEHAVIORAL
Intervention: MAPS
Description: 12 counseling phone calls over 1 year, lasting about 20-30 minutes.
Study NCT04205071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin
Description: Given PO
Study NCT04205071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lorcaserin Hydrochloride
Description: Given PO
Study NCT04205071 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02024633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: icotinib
Description: Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
Study NCT02024633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
Study NCT01652703 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT01652703 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT03912285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine10mg
Description: Amlodipine 10mg will be administered orally twice a day for 9 days
Study NCT03912285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Losartan potassium 100mg
Description: Losartan 100mg will be administered orally once a day for 9 days
Study NCT03912285 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amlodipine plus Losartan
Description: Amlodipine plus Losartan same way as arm: amlodipine and arm: losartan
Study NCT02825992 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: AcQMap System
Description: 3D imaging and mapping system for cardiac chambers
Study NCT01082120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1656
Description: Tablets orally, twice daily for 10 days
Study NCT01082120 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: Tablet oral single dose for 10 days
Study NCT02558140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO6874813
Description: RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
Study NCT02030080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Framing of feedback
Study NCT02030080 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
Study NCT02030080 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Feedback
Description: Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
Study NCT00624819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK1024805A
Description: No vaccination in this trial
Study NCT00624819 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: No vaccination in this trial
Study NCT00624819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevenar
Description: No vaccination in this trial
Study NCT00624819 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: No vaccination in this trial
Study NCT00624819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: No vaccination in this trial
Study NCT00624819 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Havrix
Description: No vaccination in this trial
Study NCT00624819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: No vaccination in this trial
Study NCT00624819 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Varilrix
Description: No vaccination in this trial
Study NCT00624819 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix
Description: No vaccination in this trial
Study NCT00822705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Control arm
Study NCT00822705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tablet
Description: Control arm
Study NCT02279771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transanal anastomotic reinforcement
Description: a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.~Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12.
Study NCT02279771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: protective ileostomy group
Description: S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
Study NCT02279771 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: a circular anal dilator (CAD)
Description: Epo Flier, SapiMed SPA, Alessandria, Italy
Study NCT02558140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RO6874813
Description: RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
Study NCT00823394 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
Study NCT00823394 — intervention group
Intervention type: OTHER
Intervention: Body Measurements
Description: Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
Study NCT00823394 — intervention group
Intervention type: BEHAVIORAL
Intervention: Self-help Materials
Description: Information on how to lower risk for developing cancer.
Study NCT03500627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OP-101
Description: Intravenous Injection of OP-101 in healthy volunteers.
Study NCT01502449 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DESTRESS-T
Description: Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
Study NCT01502449 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Optimized Usual Care (OUC)
Description: Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
Study NCT01499745 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation
Study NCT01499745 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: Exercise Training in Pulmonary Rehabilitation Program:~12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation
Study NCT01023230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DV-601
Description: Six injections of DV-601 administered over a period of 12 weeks.
Study NCT03909282 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lumpectomy
Description: Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
Study NCT03909282 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Partial breast irradiation prior to surgery
Description: Partial breast irradiation (PBI) will be delivered once aday for 5 days. The planned daily dose is 6 Gy prior to surgery (neo adjuvant)
Study NCT00167596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near Infrared Spectroscopy
Description: resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
Study NCT00167596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional
Description: resuscitation will be based according to Surviving Sepsis Campaign
Study NCT03673787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipatasertib
Description: Ipatasertib will be supplied as film-coated tablets in two strengths (100 and 200 mg) differentiated by size, shape, and weight of tablets. Ipatasertib tablets are packaged in high-density polyethylene bottles with desiccant.
Study NCT01023230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
Study NCT04378218 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training (HIIT)
Description: A 16 week, 3 sessions per week HIIT program from the subject's personal wheelchair, positioned near an adjustable table with an arm-ergometer affixed.
Study NCT00088985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: 10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection
Study NCT00088985 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 4 mg/kg intravenously, every 14 days
Study NCT00088985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine ditartrate
Description: Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
Study NCT03673787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab will be supplied as a single-use 20 mL USP/Ph. Eur Type 1 glass vial as a colourless-to-slightly-yellow, sterile, preservative-free clear liquid solution intended for intravenous (IV) administration.
Study NCT01595698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.~Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise.
Study NCT01595698 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
Study NCT01779102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb
Description: C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
Study NCT01779102 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tuberculin PPD RT 23 SSI
Description: Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
Study NCT01779102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-Tb / Tuberculin PPD RT 23 SSI
Description: The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
Study NCT02654288 — intervention group
Intervention type: OTHER
Intervention: gemcitabine-based chemotherapy
Study NCT00814190 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Intervention
Description: The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
Study NCT02518087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: oXiris®
Description: oXiris® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication \[oXiris® (Baxter Gambro)\].~Blood flow between 200-250 mL/min will be derivatised from the CPB circuit (arterial positive pressure line just after the oxygenator) into the PrismafleX eXeed™, so that it all flows thru the oXiris® membrane and returned to the CPB circuit into the venous reservoir just before the oxygenator. oXiris® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time.
Study NCT00864669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin HCl 500 mg tablets, single dose
Description: A: Experimental Subjects received Purepac formulated products under non-fasting conditions
Study NCT00864669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CLUCOPHAGE® XR 500 mg tablets, single dose
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Study NCT01357135 — intervention group
Intervention type: DRUG
Intervention: Metformin
Study NCT01357135 — intervention group
Intervention type: DRUG
Intervention: Sitagliptin
Study NCT01586676 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SAU
Description: Supervision-as-usual
Study NCT01586676 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MIA: STEP
Description: Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
Study NCT03068130 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Capsules of Bardoxolone methyl
Study NCT02515058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PUROS (Ridge Preservation bone grafting surgery)
Description: Ridge preservation bone grafting after tooth extraction
Study NCT02515058 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FDBA (Ridge Preservation bone grafting surgery)
Description: Ridge preservation bone grafting after tooth extraction
Study NCT00275054 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: cycles 1-6: 25 mg/m² i.v., d2-4, q28d